Group 1 - The core viewpoint of the news is that Harbin Sanlian Pharmaceutical Co., Ltd. has shown a significant stock price increase and trading activity, indicating potential investor interest and market performance [1][2]. - As of October 15, Harbin Sanlian's stock price rose by 2.03% to 13.54 CNY per share, with a total market capitalization of 4.283 billion CNY [1]. - The company has experienced a 40.31% increase in stock price year-to-date, with a recent 5-day increase of 5.95% [1]. Group 2 - Harbin Sanlian's main business revenue composition includes: large-volume infusion (32.00%), lyophilized powder injection (18.39%), solid preparations (17.39%), and small-volume injections (14.34%) [1]. - The company operates in the pharmaceutical and biological industry, specifically in chemical pharmaceuticals and preparations, with involvement in various concept sectors such as cosmetics and hypertension treatment [2]. - As of September 19, the number of shareholders decreased by 3.78% to 37,700, while the average circulating shares per person increased by 3.92% to 4,595 shares [2]. Group 3 - Harbin Sanlian has distributed a total of 677 million CNY in dividends since its A-share listing, with 158 million CNY distributed over the past three years [3]. - For the first half of 2025, the company reported a revenue of 413 million CNY, a year-on-year decrease of 21.08%, and a net profit attributable to shareholders of -92.39 million CNY, a decrease of 451.68% [2].

Group 1 - The core viewpoint of the news is that Harbin Sanlian Pharmaceutical Co., Ltd. (哈三联) has shown fluctuations in stock performance, with a year-to-date increase of 38.96% and a recent decline over the past 20 and 60 days [1][2] - As of October 14, the stock price reached 13.41 yuan per share, with a market capitalization of 4.242 billion yuan and a trading volume of 20.7314 million yuan [1] - The company has seen a net inflow of main funds amounting to 1.7969 million yuan, with significant buying and selling activity [1] Group 2 - For the first half of 2025, the company reported an operating income of 413 million yuan, a year-on-year decrease of 21.08%, and a net profit attributable to shareholders of -92.39 million yuan, a decrease of 451.68% [2] - The number of shareholders decreased by 3.78% to 37,700, while the average circulating shares per person increased by 3.92% to 4,595 shares [2] Group 3 - Since its A-share listing, the company has distributed a total of 677 million yuan in dividends, with 158 million yuan distributed over the past three years [3]

证券代码：002900 证券简称：哈三联 公告编号：2025-060 哈尔滨三联药业股份有限公司 梁延飞先生拟减持股份为首次公开发行前已持有的股份及因资本公积转增 股本而相应增加的股份、股权激励计划授予限制性股票解锁股份。 关于董事、高级管理人员减持股份计划期限届满的公告 董事、副总裁、董事会秘书梁延飞先生，董事朱自红先生、财务总监赵志成 先生保证向本公司提供的信息内容真实、准确、完整，没有虚假记载、误导性陈 述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息一致。 哈尔滨三联药业股份有限公司（以下简称"公司"）于 2025 年 6 月 13 日在指 定信息披露媒体《中国证券报》、《上海证券报》、《证券时报》及巨潮资讯网 （www.cninfo.com.cn）披露了《公司关于董事、高级管理人员减持股份的预披露 公告》(公告编号：2025-033)，董事、副总裁、董事会秘书梁延飞先生，董事朱 自红先生、财务总监赵志成先生计划自前述公告披露之日起 15 个交易日后的 3 个月内（即 2025 年 7 月 7 日-2025 年 10 月 6 日，且窗口期不减持），以集中竞 价方式分别减持本 ...

Core Viewpoint - On September 30, a total of 5 listed companies experienced the lifting of restrictions on their shares, with a total market value of approximately 7.641 billion yuan [1] Summary by Category Restricted Shares Release - The companies and their respective restricted shares released are as follows: - Fantuo Shuchuang (凡拓数创) - Stock Code: 301313 - Type: Pre-issue restricted shares - Released Shares: 33.5425 million [1] - Hasanlian (哈三联) - Stock Code: 002900 - Type: Equity incentive restricted shares - Released Shares: 1.9816 million [1] - Oujing Technology (欧晶科技) - Stock Code: 001269 - Type: Pre-issue restricted shares - Released Shares: 10.9 million [1] - Bofei Electric (博菲电气) - Stock Code: 001255 - Type: Pre-issue restricted shares - Released Shares: 6 million [1] - Helin Weina (和林微纳) - Stock Code: 688661 - Type: Not specified - Released Shares: 141,200 [1]

Core Viewpoint - The company has successfully achieved the conditions for the third unlock period of its 2022 restricted stock incentive plan, allowing 166 eligible participants to unlock a total of 1,963,555 shares, which represents 0.6207% of the company's total share capital [2][16][18]. Summary by Sections Incentive Plan Overview - The 2022 restricted stock incentive plan was approved on July 29, 2022, with the first grant date set for August 29, 2022, and the first unlock date for September 30, 2025 [3][5][10]. Unlock Conditions - The unlock conditions for the third period have been met, allowing 166 participants to unlock 1,963,555 shares [2][16][19]. - The shares will be available for trading starting from October 9, 2025 [16]. Adjustments and Changes - The total number of eligible participants has changed from 177 to 176 due to one participant's departure, resulting in a reduction of the total shares granted from 6,815,183 to 6,775,183 [11][12]. - The repurchase price for the restricted shares has been adjusted multiple times, currently set at 6.48 yuan per share [14]. Legal and Compliance - The company has obtained necessary approvals and legal opinions confirming compliance with relevant regulations regarding the incentive plan and share repurchase [18][19]. - The independent financial advisor has stated that the actions taken do not harm the interests of the company or its shareholders [19]. Board and Committee Opinions - The board's remuneration and assessment committee, as well as the independent directors, have confirmed the legitimacy of the unlock conditions and the eligibility of the participants [17][18].

哈尔滨三联药业股份有限公司 证券代码：002900 证券简称：哈三联 公告编号：2025-059 3、2022 年 7 月 30 日，公司披露了《独立董事关于公开征集表决权的公告》， 独立董事王福胜先生作为征集人就公司将于 2022 年第二次临时股东大会审议的 2022 年限制性股票激励计划相关议案向公司全体股东征集委托投票权。 关于 2022 年限制性股票激励计划第三个解除限售期解除限售股 份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 特别提示： 1、哈尔滨三联药业股份有限公司（以下简称"公司"）2022 年限制性股票激 励计划（以下简称"本激励计划"、"激励计划"）第三个解除限期解除限售条件已 经成就，符合解除限售条件的激励对象共 166 名，本次限制性股票解除限售的股 票数量为 1,963,555 股，占公司目前总股本的 0.6207%。 2、本次解除限售股票上市流通的时间为：2025 年 10 月 9 日 公司于 2025 年 9 月 17 日召开第四届董事会第二十四次会议与第四届监事会 第十九次会议，审议通过了《关于 202 ...

Group 1: Board Meeting Overview - The fourth meeting of the Board of Directors of Harbin Sanlian Pharmaceutical Co., Ltd. was held on September 22, 2025, via electronic communication [2][3] - All 9 directors were present at the meeting, and it was chaired by Chairman Qin Jianfei [4][5] - The meeting complied with relevant laws and regulations, including the Company Law of the People's Republic of China [5] Group 2: Resolutions Passed - The Board approved the proposal to use idle self-owned funds for entrusted financial management [6][8] - The voting results showed 9 votes in favor, with no votes against or abstentions [7] Group 3: Supervisory Meeting Overview - The fourth meeting of the Supervisory Board was also held on September 22, 2025, in person [13] - All 3 supervisors attended the meeting, which was chaired by Chairman Zhai Yuping [13][14] - The meeting adhered to legal and regulatory requirements [13] Group 4: Supervisory Resolutions - The Supervisory Board approved the same proposal regarding the use of idle self-owned funds for entrusted financial management, stating it would not affect the company's daily operations [14][15] Group 5: Financial Management Proposal - The company plans to use up to RMB 300 million of idle self-owned funds for entrusted financial management within one year [18][19] - The investment aims to enhance the efficiency of fund usage and ensure the preservation and appreciation of funds [19] - The funds will be invested in high-credit, liquid financial instruments through qualified financial institutions [19] Group 6: Investment Risk Management - The company will select safe and liquid financial products and monitor the investment closely to mitigate risks [22][24] - Internal audits will be conducted to ensure compliance and proper management of the invested funds [24] Group 7: Impact on the Company - The use of idle funds for financial management is expected to improve fund efficiency and generate investment returns without affecting the company's normal operations [24][25]

登录新浪财经APP 搜索【信披】查看更多考评等级 声明：市场有风险，投资需谨慎。 本文为AI大模型基于第三方数据库自动发布，任何在本文出现的信 息（包括但不限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成 个人投资建议。受限于第三方数据库质量等问题，我们无法对数据的真实性及完整性进行分辨或核验， 因此本文内容可能出现不准确、不完整、误导性的内容或信息，具体以公司公告为准。如有疑问，请联 系biz@staff.sina.com.cn。 会议审议并通过《关于使用闲置自有资金进行委托理财的议案》，有效表决9票，同意9票，反对0票， 弃权0票，表决结果为通过。《关于使用闲置自有资金进行委托理财的公告》详见同日刊登在公司指定 信息披露媒体《中国证券报》《上海证券报》《证券时报》及巨潮资讯网（http://www.cninfo.com.cn） 上的相关公告。 点击查看公告原文>> 责任编辑：小浪快报 哈三联（证券代码：002900 ，证券简称：哈三联 ，公告编号：2025 - 056 ）于2025年9月22日以通讯表 决的方式召开第四届董事会第二十五次会议。本次会议应到董事9名，实际出席9名 ...

（文章来源：证券日报） 证券日报网讯哈三联9月22日在互动平台回答投资者提问时表示，根据中国证券登记结算公司最新数据 显示，截至2025年9月19日，公司股东人数为37，661户。 ...

哈尔滨三联药业股份有限公司 关于使用闲置自有资金进行委托理财的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 哈尔滨三联药业股份有限公司（以下简称"公司"）于 2025 年 9 月 22 日召开 第四届董事会第二十五次会议、第四届监事会第二十次会议，审议通过了《关于 使用闲置自有资金进行委托理财的议案》，为了更好的提高闲置自有资金的使用 效率，实现资金的保值与增值，根据公司整体资金安排规划，拟使用不超过（含） 人民币 30,000 万元的闲置自有资金进行委托理财。使用期限自本次董事会审议 通过之日起一年内有效。该额度在使用期限内可以循环使用。现将具体情况公告 如下： 一、投资情况概述 1、投资目的：在确保不影响公司正常经营和资金安全的情况下，使用部分 闲置自有资金进行委托理财，以提高自有资金的使用效率、合理利用闲置自有资 金增加公司收益、更好地实现公司资金的保值与增值，维护公司股东的利益。 2、投资品种：公司将按照相关规定严格控制风险，选择资信状况及财务状 况良好、无不良诚信记录及盈利能力强的合格专业理财机构作为受托方，包括商 业银行、证券公司、基金公司 ...